CAR-T cell therapy: pharmacology
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
CAR-T cell therapy: pharmacology. Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel. Fully referenced neurology checklist.
CAR-T cell agents
- Tisagenlecleucel
- Axicabtagene ciloleucel
- Lisocabtagene maraleucel
Pharmacology
Locked: subscribe to see this section.
Indications
Locked: subscribe to see this section.
Neurotoxicity syndromes
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020 (Online ahead of print).
- Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020; 4:3943-3951.
- Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol 2023 (Online ahead of print).
- Belin C, Devic P, Ayrignac X, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020; 10:18997.
- Kuboki M, Umezawa Y, Motomura Y, et al. Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo 2021; 35:3407-3411.
